drugset / Trial / NCT01429259

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

NCT01429259

Phase 4 Completed 30 enrolled Joseph Kuti Thrasher Research Fund · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation. Safety and practicality of administering meropenem as a 3 hour infusion will be measured.

Timeline

Start
2012-02
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Meropenem Small molecule 40 mg/kg